keyword
MENU ▼
Read by QxMD icon Read
search

topical cyclosporin

keyword
https://www.readbyqxmd.com/read/29777856/ocular-irritation-and-cyclosporine-a-distribution-in-the-eye-tissues-after-administration-of-solid-lipid-microparticles-in-the-rabbit-model
#1
Eliza Wolska, Małgorzata Sznitowska, Juliusz Chorążewicz, Oliwia Szerkus, Aleksandra Radwańska, Michał J Markuszewski, Roman Kaliszan, Krystyna Raczyńska
The aim of this study was to investigate the in vivo effect of Solid Lipid Microparticles (SLM), proposed for topical ocular administration of cyclosporine, on the rabbit eye. SLM carrier is an aqueous dispersion of lipid microparticles (20% w/w) with a size up to 15 μm. Cyclosporine was dissolved in the formulation in the concentration of 0.5 or 2.0% (w/w). Ocular tolerance of microsphere dispersion was assessed in rabbit model by the Draize eye test (SLM was compared with emulsion and oily solution), and cyclosporine distribution in ocular tissues was evaluated after multiple application of tested formulations (SLM dispersions, emulsions and oily solution) for 7 days...
May 16, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29753904/sorbitan-ester-nanoparticles-sens-as-a-novel-topical-ocular-drug-delivery-system-design-optimization-and-in-vitro-ex-vivo-evaluation
#2
Jesus Alvarez-Trabado, Antonio López-García, Manuel Martín-Pastor, Yolanda Diebold, Alejandro Sanchez
We explored the potential of two types of sorbitan ester nanoparticles (SENS) as novel tools for topical ocular drug delivery. The optimized SENS formulation (SENS-OPT) consisted of nanoparticles (NPs) of 170.5 nm, zeta potential +33.9 mV, and cyclosporine loading of 19.66%. After hyaluronic acid (HA) coating, the resulting SENS-OPT-HA NPs had a particle size of 177.6 nm and zeta potential of -20.6 mV. The NPs were stable during 3 months of storage at different temperatures and did not aggregate in the presence of protein-enriched simulated lacrimal fluid...
May 10, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29734357/cyclosporine-a-drug-delivery-system-for-high-risk-penetrating-keratoplasty-stabilizing-the-intraocular-immune-microenvironment
#3
Ting Zhang, Zhiyuan Li, Ting Liu, Suxia Li, Hua Gao, Chao Wei, Weiyun Shi
Cyclosporine A (CsA) is an essential medication used to prevent corneal allograft rejection. Our preliminary studies revealed that CsA drug-delivery system (DDS) was more effective in preventing high-risk corneal allograft rejection than topical CsA application. However, the impacts of CsA DDS on the intraocular immune microenvironment were not fully elucidated. In the present study, we investigated the effect of CsA DDS on the cornea allograft, aqueous humor, and iris-ciliary body using a rabbit model of high-risk penetrating keratoplasty...
2018: PloS One
https://www.readbyqxmd.com/read/29729105/cost-effectiveness-of-secukinumab-as-first-biologic-treatment-compared-with-other-biologics-for-moderate-to-severe-psoriasis-in-germany
#4
Matthias Augustin, Doreen McBride, Isabelle Gilloteau, Caitriona O'Neill, Katja Neidhardt, Christopher N Graham
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, has demonstrated strong and sustained efficacy in adults with moderate to severe psoriasis in clinical trials. OBJECTIVE: This analysis compared the cost per responder of secukinumab as first biologic treatment of moderate to severe psoriasis, with adalimumab, infliximab, etanercept, and ustekinumab in Germany. METHODS: A 52-week decision-tree model was developed...
May 5, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29704273/alitretinoin-can-be-a-good-treatment-option-for-idiopathic-recalcitrant-trachyonychia-in-adults-an-open-label-study
#5
Kihyuk Shin, Tae-Wook Kim, Sung-Min Park, Hyun-Joo Lee, Hyunju Jin, Hyang-Suk You, Woo-Haing Shim, Gun-Wook Kim, Hoon-Soo Kim, Hyun-Chang Ko, Byung-Soo Kim, Moon-Bum Kim
BACKGROUND: Trachyonychia can be refractory to conventional treatments including topical, intralesional, or systemic corticosteroids, as well as cyclosporine and retinoids. Therefore, new treatment options are needed for recalcitrant trachyonychia. OBJECTIVE: To evaluate the efficacy and safety of oral alitretinoin for idiopathic recalcitrant trachyonychia. METHODS: A total of 21 adult patients with 210 nails affected by idiopathic recalcitrant trachyonychia were evaluated in this open-label prospective study...
April 28, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29702077/phosphosulindac-is-efficacious-in-an-improved-concanavalin-a-based-rabbit-model-of-chronic-dry-eye-disease
#6
Robert A Honkanen, Liqun Huang, Gang Xie, Basil Rigas
Dry eye disease (DED), an inflammatory disease of the ocular surface, affects 15% of humans worldwide. No satisfactory treatment exists for DED partly because of the lack of informative animal models of this disease. We evaluated the anti-inflammatory phosphosulindac (PS) for the treatment of DED using a new rabbit model of chronic DED. In this model, based on the concanavalin A (Con A) acute DED model, we injected all lacrimal glands with Con A 3 times weekly under ultrasound guidance, which prolonged DED to >3 weeks, and used concurrently 4 parameters of efficacy: tear break-up time (TBUT), tear osmolarity, Schirmer test, and tear lactoferrin levels, making efficacy assessment robust...
April 10, 2018: Translational Research: the Journal of Laboratory and Clinical Medicine
https://www.readbyqxmd.com/read/29698819/development-of-microemulsions-of-suitable-viscosity-for-cyclosporine-skin-delivery
#7
Marta Benigni, Silvia Pescina, Maria Aurora Grimaudo, Cristina Padula, Patrizia Santi, Sara Nicoli
Psoriasis is a widespread chronic disease affecting 2-4% of the population in Western countries. Its mild-to-moderate form, representing approximately 80% of the total cases, is treated by topical application, with corticosteroid being the standard treatment. However, in case of psoriasis, no single treatment works for every patient and optimizing topical therapy is a key aspect. A possible alternative is represented by cyclosporine, an immunosuppressant cyclic peptide administered orally in the treatment of the severe form...
April 23, 2018: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29681334/placebo-effects-in-the-immune-system
#8
Martin Hadamitzky, Wiebke Sondermann, Sven Benson, Manfred Schedlowski
Even though knowledge and systematic application of placebo responses in the immune system are sparse, this topic is of particular importance since it may aim at drug-dose reduction while maintaining therapeutic efficacy of treatment in clinical settings. Placebo responses in the immune system are inducible by associated learning paradigms, such as behaviorally conditioned immunosuppression. One established learning paradigm in both rats and humans is conditioned taste avoidance (CTA), where a novel taste as conditioned stimulus (CS) is paired with the administration of the immunosuppressive drug cyclosporine A (CsA) as unconditioned stimulus...
2018: International Review of Neurobiology
https://www.readbyqxmd.com/read/29676072/current-management-of-moderate-to-severe-atopic-dermatitis-a-survey-of-allergists-pediatric-allergists-and-dermatologists-in-korea
#9
Hye Yung Yum, Hyun Hee Kim, Hyun Jung Kim, Woo Kyung Kim, So Yeon Lee, Kapsok Li, Dong Hun Lee
PURPOSE: There is an unmet need for the treatment of moderate-to-severe atopic dermatitis (AD), leading to variation in management strategies. To investigate distinct features and treatment modalities according to physicians' specialties, we collected data on the current treatment approach to moderate-to-severe AD among allergists, pediatric allergists and dermatologists in Korea. METHODS: This questionnaire-based study was administered to physicians from the Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI), Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD), and Korean Atopic Dermatitis Association (KADA)...
May 2018: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/29675376/clinical-efficacy-of-combined-topical-0-05-cyclosporine-a-and-0-1-sodium-hyaluronate-in-the-dry-eyes-with-meibomian-gland-dysfunction
#10
Ho-Yun Kim, Ji-Eun Lee, Ha-Na Oh, Ju-Whan Song, Sang-Youp Han, Jong-Soo Lee
AIM: To investigate the efficacy of combined topical 0.05% cyclosporine A (CsA; Restasis® , Allergan pharmaceuticals, USA) and 0.1% sodium hyaluronate treatment in dry eyes with meibomian gland dysfunction (MGD). METHODS: In a retrospective analysis, 53 patients (106 eyes) with MGD were enrolled and performed lid warm massage for 10min daily and be instilled preservative free sodium hyaluronate 0.1% eye drops 4 times daily. Patients were divided into subjects treated with topical 0...
2018: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/29670328/treatment-outcomes-in-the-dry-eye-amniotic-membrane-dream-study
#11
Marguerite B McDonald, Hosam Sheha, Sean Tighe, Susan B Janik, Frank W Bowden, Amit R Chokshi, Michael A Singer, Seema Nanda, Mujtaba A Qazi, Damon Dierker, Adam T Shupe, Brittany J McMurren
Purpose: To evaluate the efficacy of cryopreserved amniotic membrane (CAM) in reducing signs and symptoms of dry eye disease (DED) in a large patient population. Methods: A retrospective chart review at 10 clinical sites was done of patients with refractory DED who received CAM and completed at least 3 months of follow-up. Data collected were demographics; medical history including previous and current ocular treatment, diagnosis, clinical presentations, comorbidity, duration and frequency of treatment with CAM; and concomitant medications...
2018: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29615833/patient-and-physician-perspectives-on-the-use-of-cyclosporine-ophthalmic-emulsion-0-05-for-the-management-of-chronic-dry-eye
#12
REVIEW
Tatiana Deveney, Penny A Asbell
Dry eye disease (DED) is a multifactorial disease of the ocular surface and is one of the most common reasons for patients to visit an eye care provider. Cyclosporine A (CsA) is an immune modulating drug that was approved in the US for topical use in the treatment of DED in 2003, which led to a paradigm change in our understanding and treatment of DED, turning attention to control of inflammation for treatment. This review summarizes the literature to date regarding the impact of CsA on the treatment of DED...
2018: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29610161/topical-hypochlorite-and-skin-acidification-improves-erythroderma-of-omenn-syndrome
#13
Margaret Wat, Arielle Olicker, Howard Meyerson, Susan Nedorost, Amy S Paller, Kevin Cooper
We describe a case of Omenn syndrome displaying exudative erythroderma and other characteristic features, including alopecia, absent B and naïve T cells, hyper immunoglobulin E levels, and eosinophilia. A pathogenic recombination-activating RAG1 homozygous genetic mutation confirmed the diagnosis. She required frequent antibiotics at both treatment and prophylactic doses, which alone did not control her erythroderma, but her high risk of infection precluded the use of systemic agents such as cyclosporine, which would further suppress her already severely compromised immune system...
April 2018: Pediatrics
https://www.readbyqxmd.com/read/29579456/targeting-the-plasticity-of-psoriasis
#14
Jack L Arbiser, Justin Elsey
Psoriasis is a common inflammatory condition found in 1-2% of the population. The greatest advances in psoriasis treatment have occurred in patients with severe psoriasis, moving from systemic small molecules including methotrexate, cyclosporine, and retinoids to targeted agents against psoriasis-associated cytokines, such as TNF-α, IL-12, IL-23, and IL-17. Although the new biologics do not have the same adverse effects as the systemic drugs, they do predispose to systemic infections (and perhaps cancer), and they are extremely expensive...
April 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29575224/oral-psoriasis-and-sibo-is-there-a-link
#15
LETTER
F Drago, G Ciccarese, V Cordara, M Paudice, A Herzum, A Parodi
No abstract text is available yet for this article.
March 24, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29573491/generalized-pustular-psoriasis-a-review-and-update-on-treatment
#16
REVIEW
K M Hoegler, A M John, M Z Handler, R A Schwartz
Generalized pustular psoriasis (GPP) is a subtype of pustular psoriasis characterized by painful and occasionally disfiguring cutaneous manifestations with sepsis-like systemic symptoms. Affecting any age and race, GPP can occur with other forms of psoriasis or by itself. Stimuli for flares include medications, infections and environmental triggers. The interleukin family and caspase recruitment domain family have been implicated in its pathogenesis. Other forms of pustular psoriasis include impetigo herpetiformis, palmoplantar pustular psoriasis, annular pustular psoriasis and acrodermatitis continua of Hallopeau...
March 24, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29557246/dupilumab-for-treatment-of-atopic-dermatitis
#17
Marlene Seegräber, Jerome Srour, Alexandra Walter, Macarena Knop, Andreas Wollenberg
Dupilumab is a new treatment option for patients with moderate-to-severe atopic dermatitis. It blocks IL-4/IL13-signaling and thereby inhibits receptor signaling downstream the JAK-STAT-pathway. Three of the main disease mechanisms of atopic dermatitis are affected by blocking this pathway; the decrease of skin barrier function, the class switch to IgE and the TH2-differentiation. Areas Covered: Dupilumab showed promising results in clinical trials of phase I-III. Clinical outcome parameters such as SCORAD, EASI, IGA and BSA improved with dupilumab...
March 20, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29552874/allergic-conjunctivitis-current-concepts-on-pathogenesis-and-management
#18
M Sacchetti, I Abicca, A Bruscolini, C Cavaliere, M Nebbioso, A Lambiase
Allergic conjunctivitis (AC) includes a wide spectrum of clinical entities characterized by different incidence, age of onset, natural course, clinical outcome and response to treatment. Taken together, they represent one of the most frequent ocular surface diseases affecting more than 30% of the young-adult population and show an increasing incidence over the years. Moreover, comorbidities with other systemic atopic conditions such as asthma, atopic dermatitis and rhinitis require a multidisciplinary approach...
January 2018: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/29542298/immediate-hypersensitivity-reactions-induced-by-triamcinolone-in-a-patient-with-atopic-dermatitis
#19
Jee Hee Son, Sook Young Park, Yong Se Cho, Bo Young Chung, Hye One Kim, Chun Wook Park
Corticosteroids are potent anti-inflammatory and anti-allergic agents used in the treatment of various inflammatory diseases, including allergic disease. They are frequently considered the therapy-of-choice for many skin diseases. However, allergic reactions caused by corticosteroids have been reported. Among these, delayed reactions to topical steroids are more common, whereas immediate reactions to systemic steroids are rare. Herein, we report the case of a 32-year-old woman with triamcinolone-induced immediate hypersensitivity reaction, in which the patient had a positive prick test result with triamcinolone...
March 19, 2018: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/29529104/psoriasis-treatment-in-hiv-positive-patients-a-systematic-review-of-systemic-immunosuppressive-therapies
#20
Mio Nakamura, Michael Abrouk, Benjamin Farahnik, Tian H Zhu, Tina Bhutani
The management of psoriatic disease in the human immunodeficiency virus (HIV)-positive population is challenging. The clinical course often is progressive and refractory; therefore, first- and second-line therapies including topical agents, phototherapy, and oral retinoids often are inadequate. Most other currently available systemic therapies for psoriatic disease are immunosuppressive, which poses a distinct clinical challenge. A comprehensive systematic review of the literature via a PubMed search of articles indexed for MEDLINE using the terms psoriasis and HIV and psoriatic arthritis and HIV combined with several systemic immunosuppressive agents yielded a total of 25 reported cases of systemic immunosuppressive therapies used to treat psoriatic disease in HIV-positive patients including methotrexate, cyclosporine, etanercept, adalimumab, infliximab, and ustekinumab...
January 2018: Cutis; Cutaneous Medicine for the Practitioner
keyword
keyword
36427
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"